View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
February 11, 2022

China grants approval to GSK’s Benlysta for lupus nephritis treatment

The approval is based on findings from the Phase III BLISS-LN clinical trial of belimumab in adults with active LN.

China’s National Medical Products Administration (NMPA) has granted approval to GlaxoSmithKline’s (GSK) Benlysta (belimumab) to treat active lupus nephritis (LN) in adults.

The treatment is intended for LN patients who are currently receiving standard of care (SoC). 

A specific inhibitor of B-lymphocyte stimulator (BLyS), Benlystais a human monoclonal antibody that attaches to soluble BLyS. 

Earlier, Benlysta was approved in China as an add-on treatment in individuals aged five years and above with active systemic lupus erythematosus (SLE). 

With the latest development, the antibody became the first and only biologic treatment to obtain approval for SLE and LN in the country.

The approval is based on results from the randomised, double-blind, placebo-controlled Phase III BLISS-LN clinical trial that analysed the safety and efficacy of intravenous (IV) doses of 10mg/kg belimumab along with SoC versus placebo plus SoC in adults with active LN. 

According to the findings, the treatment with belimumab plus SoC over two years boosted renal response rates and aided in lowering the risk of kidney disease deterioration in active LN patients versus SoC alone.

Furthermore, the trial of 448 adult subjects met its primary endpoint.

A statistically significant and clinically meaningful number of subjects or 43% attained Primary Efficacy Renal Response in the belimumab arm versus 32% in the placebo arm at 104 weeks.

GSK R&D chief scientific officer and president Hal Barron said: “Nearly 500,000 people in China have systemic lupus erythematosus and more than half of these patients will develop one of the most common and serious complications, lupus nephritis.

“Recognising that lupus nephritis can lead to kidney damage, this approval will allow patients in China access to a new treatment option to help slow the progressive nature of systemic lupus.”

In April 2019, the US Food and Drug Administration (FDA) granted approval to Benlysta for the treatment of children with SLE.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU